Federal Register of Legislation - Australian Government

Primary content

PB 71 of 2009 Specifications as made
This Specification determines pharmaceutical benefits that can be resupplied inside 20 days on the one prescription.
Administered by: Health
Registered 29 Jul 2009
Tabling HistoryDate
Tabled HR11-Aug-2009
Tabled Senate11-Aug-2009
Date of repeal 19 Mar 2014
Repealed by Health (Spent and Redundant Instruments) Repeal Regulation 2014

 

COMMONWEALTH OF AUSTRALIA

Instrument number PB 71 of 2009

National Health (Pharmaceutical Benefits – Early Supply) Amendment August 2009 - Specification Under Subsection 84AAA(2)

 

Amendment determination under subsection 84AAA(2) of the National Health Act 1953

 

I, Linda Jackson, Assistant Secretary, Pharmaceutical Evaluation Branch, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.

 

Dated          24               July 2009

 

 

LINDA JACKSON

Assistant Secretary

Pharmaceutical Evaluation Branch

Department of Health and Ageing

 

 

 

Amendment determination — Pharmaceutical Benefits-Early Supply

 

 

1          Name of Instrument

 

(1)           This Instrument is the National Health Act (Pharmaceutical Benefits – Early Supply) Amendment August 2009 - specification under subsection 84AAA(2).

 

(2)           This Instrument may also be cited as “No. PB 71 of 2009”.


 

2          Commencement

 

This Instrument commences on 1 August 2009.

 

 

3          Amendment of PB 30 of 2009

 

Schedule 1 amends the National Health (Pharmaceutical Benefits – Early Supply) Instrument 2009, PB 30 of 2009.

 


Schedule 1        Amendments

[1]                                  Schedule 1, item dealing with Etanercept

insert in the columns in the order indicated:

 

 

Injection 50 mg in 1 mL single use injection pen, 4

Injection

1

5

 

 

[2]                                  Schedule 1, item dealing with Oestradiol and oestradiol with norethisterone

omit from the columns in the order indicated:

 

 

Transdermal patches containing 510 micrograms oestradiol (as hemihydrate) with 4.8 mg norethisterone acetate, 8

Transdermal

1

5

 

Transdermal patches containing 620 micrograms oestradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8

Transdermal

1

5

 

 

and substitute columns after the item dealing with Oestradiol and oestradiol with norethisterone in the order indicated:

 

Oestradiol with norethisterone

Transdermal patches containing 510 micrograms oestradiol (as hemihydrate) with 4.8 mg norethisterone acetate, 8

Transdermal

1

5

 

Transdermal patches containing 620 micrograms oestradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8

Transdermal

1

5

 

 

[3]                                  Schedule 1, item dealing with Risedronate sodium

omit from the column “Listed drug”:

          Risedronate sodium

and substitute:

          Risedronic acid

 

[4]                                  Schedule 1, after item dealing with Temozolomide

insert in the columns in the order indicated:

 

Teriparatide

Injection 250 micrograms per mL, 2.4 mL in multi-dose pre-filled pen

Injection

1

5